Medical technologies for the diagnosis of prostate cancer.
Prostate cancer is an extremely prevalent problem, especially in our aging population. The prostate-specific antigen test has revolutionized prostate cancer screening. Significant advances have been made in the usage of prostate-specific antigen and its derivatives, biomarkers, diagnostic imaging techniques, biopsy strategy, biopsy needle design and anesthetic agents. Further improvement in prostate cancer detection hinges on the development of an imaging technique that is tumor specific and sensitive to biological aggressiveness.
Fitzsimons
Nicholas J
NJ
Division of Urologic Surgery and Duke Prostate Center, Duke University Medical Center, Durham, NC 27710, USA. nicholas.fitzsimons@duke.edu
Sun
Leon
L
Moul
Judd W
JW
D014408:Biomarkers, Tumor / Q000032:analysis*; D001706:Biopsy / Q000379:methods*; D001709:Biotechnology / Q000379:methods; D003952:Diagnostic Imaging / Q000379:methods*; D005820:Genetic Testing / Q000379:methods*; D006801:Humans; D008297:Male; D013677:Medical Laboratory Science / Q000379:methods; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000175:diagnosis*
D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen